Fiche publication
Date publication
juin 2026
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
,
Pr MANFREDI Sylvain
Tous les auteurs :
Decraecker M, Bourien H, Thiam EM, Edeline J, Koudjou-Sonegueng A, Merle P, Blanc JF, Amaddeo G, Uguen T, Decaens T, Ganne-Carrie N, Silvain C, Bouattour M, Riachi G, Allaire M, Cattan S, Adhoute X, Gratien M, Anty R, Peron JM, Oberti F, Baron A, Pascale A, Pageaux GP, Manfredi S, Nousbaum JB, Lequoy M, Jaillais A, Ollivier-Hourmand I, Gelu-Simeon M, Bronowicki JP, Heurgue A, Villing AL, Rosa I, Cadranel JF, Ducournau G, Ganry O, Costentin C, Nguyen-Khac E,
Lien Pubmed
Résumé
Unresectable hepatocellular carcinoma (HCC) remains a major global health burden. Immunotherapy-based combinations have become the standard of care in first-line (1L) treatment, but evidence on subsequent therapies is limited. This study aimed to describe access to and outcomes of second-line (2L) treatments following atezolizumab-bevacizumab (AB) compared with sorafenib (Sor), using real-world data from the French prospective CHIEF cohort.
Mots clés
hepatocellular carcinoma (HCC), immunotherapy, outcomes, prognosis, systemic treatments
Référence
JHEP Rep. 2026 06 11;:101904
